SHPHF'
s EV-to-FCF Range Over the Past 10 Years
Min: -101.95 Med: 2.63 Max: 148.26
Current: -21.88
During the past 13 years, the highest EV-to-FCF of Sihuan Pharmaceutical Holdings Group was 148.26. The lowest was -101.95. And the median was 2.63.
SHPHF's EV-to-FCF is ranked worse than 100% of 559
companies
in the Drug Manufacturers industry
Industry Median: 19.97
vs SHPHF: -21.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sihuan Pharmaceutical Holdings Group's PE Ratio (TTM) for today is calculated as:
Sihuan Pharmaceutical Holdings Group's share price for today is $0.1297.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sihuan Pharmaceutical Holdings Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sihuan Pharmaceutical Holdings Group EV-to-FCF Related Terms
Sihuan Pharmaceutical Holdings Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's EV-to-FCF falls into.
Sihuan Pharmaceutical Holdings Group's current Enterprise Value is $665.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sihuan Pharmaceutical Holdings Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-30.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a EV-to-FCF of -21.88 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #999999 out of 559 companies in the Drug Manufacturers industry.
Is Sihuan Pharmaceutical Holdings Group's EV-to-FCF too high?
Sihuan Pharmaceutical Holdings Group's current EV-to-FCF is -21.88. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #999999 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #999999 out of 559 companies for EV-to-FCF. This places Sihuan Pharmaceutical Holdings Group in the lower half of its industry. The industry median EV-to-FCF is 19.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.97, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current EV-to-FCF is -21.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.18, compared to a current price of $0.13 — trading 27.9% below its estimated fair value. The current EV-to-FCF is -21.88. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current EV-to-FCF is -21.88 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.13 is trading 27.9% below its estimated GF Value™ of $0.18.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
EV-to-FCF: -21.88
GF Value™: $0.18 vs. price of $0.13 (27.9% below fair value)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
51GF Score
Get the complete analysis for SHPHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
